ABC Arbitrage SA Acquires New Shares in Eli Lilly and Company $LLY

ABC Arbitrage SA bought a new position in Eli Lilly and Company (NYSE:LLY) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 1,649 shares of the company’s stock, valued at approximately $1,258,000.

Several other large investors have also recently bought and sold shares of LLY. Sumitomo Mitsui Financial Group Inc. acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $27,000. Evolution Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the second quarter valued at $29,000. Steph & Co. lifted its holdings in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the period. Financial Gravity Companies Inc. bought a new stake in shares of Eli Lilly and Company in the second quarter worth $31,000. Finally, Bare Financial Services Inc grew its stake in shares of Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 29 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion to add in vivo CAR‑T and circular RNA capabilities — a long‑term bet to broaden genetic‑medicine and cell‑therapy exposure. Lilly to acquire Orna Therapeutics to advance cell therapies
• Positive Sentiment: Lilly moved eloralintide (LY3841136) into Phase 3 for obesity, extending its leadership in weight‑loss therapeutics and potential longer‑term revenue streams beyond current GLP‑1s. Lilly Advances Eloralintide Into Phase 3, Expanding Its Obesity Drug Ambitions
• Positive Sentiment: Solbinsiran advanced in a Phase 2 study targeting high‑risk cholesterol patients, strengthening Lilly’s cardiovascular pipeline outside diabetes/obesity. Eli Lilly’s Solbinsiran Trial Advances in High-Risk Cholesterol Market
• Positive Sentiment: Strong 2025 results and 2026 guidance underpin optimism: Lilly reported large revenue and EPS growth driven by GLP‑1 sales, and analysts forecast continued double‑digit revenue and earnings expansion next year. Eli Lilly’s 2025 Surge Sets the Stage for Another Big Year in 2026
• Neutral Sentiment: Lilly expanded a large strategic collaboration with Innovent Biologics (multi‑billion potential), increasing global oncology/immunology reach but with milestone‑contingent upside. Eli Lilly Enters $8.5 Billion Strategic Collaboration with Innovent Biologics and Acquires Orna Therapeutics
• Neutral Sentiment: Deutsche Bank raised its price target on LLY, signaling continued analyst confidence, but lofty targets may already reflect much of the upside. Benzinga
• Negative Sentiment: Revenue concentration risk: over 60% of recent sales still come from GLP‑1 drugs (Mounjaro, Zepbound), leaving the stock sensitive to competitive dynamics, pricing and policy risk. Over 60% of Eli Lilly’s Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried?
• Negative Sentiment: Some shareholders trimmed positions (e.g., Bristol Gate Capital), and after the recent triple‑digit run, profit‑taking and rotation into other names likely pressure the share price in the near term. Bristol Gate Capital Partners Trims Eli Lilly Stake

Eli Lilly and Company Trading Down 1.9%

LLY opened at $1,025.06 on Wednesday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company has a market cap of $969.08 billion, a P/E ratio of 44.66, a price-to-earnings-growth ratio of 0.90 and a beta of 0.39. The company has a fifty day moving average price of $1,051.59 and a two-hundred day moving average price of $902.97.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The business’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is 30.15%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on LLY shares. The Goldman Sachs Group set a $1,260.00 target price on Eli Lilly and Company in a research report on Thursday, February 5th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. Wolfe Research upped their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Bank of America decreased their target price on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the stock a “buy” rating in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,217.71.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.